Efficacy and safety of pamidronate in Modic type 1 changes: study protocol for a prospective randomized controlled clinical trial

Stella Cecchetti, Bruno Pereira, Antoine Roche, Christophe Deschaumes, Dihya Abdi, Emmanuel Coudeyre, Jean-Jacques Dubost, Sylvain Mathieu, Sandrine Malochet-Guinamand, Anne Tournadre, Marion Couderc, Marielle Vayssade, Coline Daron, Martin Soubrier, Stella Cecchetti, Bruno Pereira, Antoine Roche, Christophe Deschaumes, Dihya Abdi, Emmanuel Coudeyre, Jean-Jacques Dubost, Sylvain Mathieu, Sandrine Malochet-Guinamand, Anne Tournadre, Marion Couderc, Marielle Vayssade, Coline Daron, Martin Soubrier

Abstract

Background: Erosive degenerative disc disease, also known as Modic type 1 changes, is usually characterized by low back pain with an inflammatory pain pattern, as seen in spondyloarthropathies. Intravenous pamidronate has proven to be effective in patients with ankylosing spondylitis who are refractory to nonsteroidal antiinflammatory drugs, and in painful bone diseases in general, such as Paget's disease, fibrous dysplasia or vertebral fractures. We therefore hypothesize that pamidronate would be effective in treating low back pain associated with Modic type 1 changes.

Methods/design: This study, called PEPTIDE (short for the French title "Etude Prospective sur l'Efficacité et la tolérance du PamidronaTe dans les dIscopathies Degeneratives Erosives"), will be a double-blind, randomized, placebo-controlled, parallel group, phase two clinical trial. A total of 48 patients will be recruited. These patients will be randomly assigned to one of the two groups, with 24 patients in each group: one group will be given pamidronate and the other a placebo. Pamidronate will be administered at a dose of 90 mg per day for two days consecutively, and every patient, irrespective of treatment group, will be given paracetamol to maintain blinding by preventing drug-induced fever. The primary outcome measure is a between-group difference of 30 points on a 100 mm Visual Analogue Scale (VAS) at three months. Secondary outcome measures are improvement in functional status and the drug's safety. Primary and secondary outcome measures will be assessed at each visit (inclusion, at six weeks, three months, and six months). If the primary goal is not attained, the patient will be offered a rigid or semi-rigid back brace, irrespective of the treatment group.

Discussion: To date, only local treatments, for example intradiscal corticosteroid therapy, lumbar arthrodesis or back braces have been studied in randomized, controlled trials, with controversial results. This trial is currently ongoing and, if conclusive, should provide physicians with an acceptable alternative to those treatments. The results should be publicly available in spring 2015.

Trial registration: ClinicalTrials.gov number, NCT01799616.

References

    1. Modic MT, Masaryk TJ, Ross JS, Carter JR. Imaging of degenerative disk disease. Radiology. 1988;168:177e86.
    1. Champsaur P, Parlier-Cuau C, Juhan V, Daumen-Legré V, Chagnaud C, Lafforgue P, Laredo JD, Kasbarian M. Differential diagnosis of infective spondylodiscitis and erosive degenerative disk disease. J Radiol. 2000 May;81:516–522.
    1. Bordet B, Borne J, Fantino O, Bousquet J-C, Coillard S. Analyse IRM selon Modic: intérêt dans les lombalgies. In Résonances Européennes du Rachis. 2005;13:1650–1652.
    1. Jensen TS, Karppinen J, Sorensen JS, Niinimäki J, Leboeuf-Yde C. Vertebral endplate signal changes (Modic change): a systematic literature review of prevalence and association with non-specific low back pain. Eur Spine J. 2008 Nov;17:1407–1422. doi: 10.1007/s00586-008-0770-2.
    1. Rahme R, Moussa R. The modic vertebral endplate and marrow changes: pathologic significance and relation to low back pain and segmental instability of the lumbar spine. AJNR Am J Neuroradiol. 2008 May;29:838–842. doi: 10.3174/ajnr.A0925.
    1. Toyone T, Takahashi K, Kitahara H, Yamagata M, Murakami M, Moriya H. Vertebral bone-marrow changes in degenerative lumbar disc disease: an MRI study of 74 patients with low back pain. J Bone Joint Surg Br. 1994;76:757–764.
    1. Weishaupt D, Zanetti M, Hodler J, Boos N. MR imaging of the lumbar spine: prevalence of intervertebral disk extrusion and sequestration, nerve root compression, end plate abnormalities, and osteoarthritis of the facet joints in asymptomatic volunteers. Radiology. 1998;209:661–666.
    1. Kjaer P, Korsholm L, Bendix T, Sorensen JS, Leboeuf-Yde C. Modic changes and their associations with clinical findings. Eur Spine J. 2006;15:1312–1319. doi: 10.1007/s00586-006-0185-x.
    1. Kjaer P, Leboeuf-Yde C, Korsholm L, Sorensen JS, Bendix T. Magnetic resonance imaging and low back pain in adults: a diagnostic imaging study of 40-year-old men and women. Spine. 2005;30:1173e80.
    1. Revel M. IRM et lombalgies. Réflexions Rhumatologiques. 2004;69:29.
    1. Bailly F, Maigne JY, Genevay S, Marty M, Gandjbakhch F, Rozenberg S, Foltz V. Inflammatory pain pattern and pain with lumbar extension associated with Modic 1 changes on MRI: a prospective case–control study of 120 patients. Eur Spine J. 2014;23:493–497. doi: 10.1007/s00586-013-3036-6.
    1. Nguyen C, Bendeddouche I, Sanchez K, Jousse M, Papelard A, Feydy A, Revel M, Poiraudeau S, Rannou F. Assessment of ankylosing spondylitis criteria in patients with chronic low back pain and vertebral endplate Modic I signal changes. J Rheumatol. 2010 Nov;37:2334–2339. doi: 10.3899/jrheum.100165.
    1. Revel M, Poiraudeau S, Lefèvre-Colau MM, Mayoux-Benhamou MA. La discopathie destructrice rapide. Rev Rhum. 2000;67:266–269.
    1. Maigne JY, Ballard M. Y'a t'il des signes cliniques de discopathie inflammatoire lombaire? Revue de Médecine Vertébrale. 2004;13:12–14.
    1. Beaudreuil J, Dieude P, Poiraudeau S, Revel M. Disabling chronic low back pain with Modic type 1 MRI signal: Acute reduction in pain with intradiscal corticotherapy. Ann Phys Rehabil Med. 2012 Apr;55:139–147. doi: 10.1016/j.rehab.2012.01.004.
    1. Buttermann GR. The effect of spinal steroid injections for degenerative disc disease. Spine J. 2004;4:495–505. doi: 10.1016/j.spinee.2004.03.024.
    1. Fayad F, Lefevre-Colau MM, Rannou F, Quintero N, Nys A, Macé Y, Poiraudeau S, Drapé JL, Revel M. Relation of inflammatory modic changes to intradiscal steroid injection outcome in chronic low back pain. Eur Spine J. 2007 Jul;16:925–931. doi: 10.1007/s00586-006-0301-y.
    1. Vital JM, Gille O, Pointillart V, Pedram M, Bacon P, Razanabola F, Schaelderle C, Azzouz S. Course of Modic 1 six months after lumbar posterior osteosynthesis. Spine (Phila Pa 1976) 2003;28:715–720.
    1. Blondel B, Tropiano P, Gaudart J, Huang RC, Marnay T. Clinical results of lumbar total disc arthroplasty in accordance with Modic signs, with a 2-year-minimum follow-up. Spine (Phila Pa 1976) 2011;36:2309–2315. doi: 10.1097/BRS.0b013e31820f7372.
    1. Hanley EN Jr, David SM. Lumbar arthrodesis for the treatment of back pain. J Bone Joint Surg Am. 1999 May;81:716–730.
    1. Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976) 2009;34:49–59. doi: 10.1097/BRS.0b013e3181909558.
    1. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol. 1998 Apr;25:714–717.
    1. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, Aaron S, Russell AS. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol. 2001 Jan;28:144–155.
    1. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS. A six-month randomized, controlled, double-blind, dose–response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 2002 Mar;46:766–773. doi: 10.1002/art.10139.
    1. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 2003 Aug;42:1018–1020. doi: 10.1093/rheumatology/keg256.
    1. Cairns AP, Wright SA, Taggart AJ, Coward SM, Wright GD. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis. 2005;64:338–339. doi: 10.1136/ard.2004.022871.
    1. Sayag-Boukris V, Loussadi I, Cormier C, Laroche F, Menkes CJ, Kahan A. Efficacy of pamidronate in the treatment of SAPHO syndrome. Arthritis Rheum. 1998;41:S114.
    1. Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A. Pamidronate treatment in SAPHO syndrome. Joint Bone Spine. 2002 Jun;69:392–396. doi: 10.1016/S1297-319X(02)00419-0.
    1. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 2004;43:658–661. doi: 10.1093/rheumatology/keh149.
    1. Soubrier M, Dubost JJ, Ristori JM, Sauvezie B, Bussière JL. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Dec;92:637–640. doi: 10.1067/moe.2001.119739.
    1. Solau-Gervais E, Soubrier M, Gerot I, Grange L, Puechal X, Sordet C, Sibilia J, Duquesnoy B. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 2006 Mar;45:339–342.
    1. Vasireddy S, Talwalkar A, Miller H, Mehan R, Swinson DR. Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. Clin Rheumatol. 2003 Dec;22:376–380. doi: 10.1007/s10067-003-0762-x.
    1. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006 Dec;21:P114–P119. doi: 10.1359/jbmr.06s222.
    1. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol. 1999;18:266–267. doi: 10.1007/s100670050099.
    1. Slobodin G, Rosner I, Feld J, Rimar D, Rozenbaum M, Boulman N, Odeh M. Pamidronate treatment in rheumatology practice: a comprehensive review. Clin Rheumatol. 2009 Dec;28:1359–1364. doi: 10.1007/s10067-009-1256-2.
    1. Poujol D, Ristori JM, Dubost JJ, Soubrier M. Efficacy of pamidronate in erosive degenerative disk disease: A pilot study. Joint Bone Spine. 2007;74:663–664. doi: 10.1016/j.jbspin.2007.04.007.
    1. Coste J, Le Parc JM, Berge E, Delecoeuillerie G, Paolaggi JB. French validation of a disability rating scale for the evaluation of low back pain (EIFEL questionnaire) Rev Rhum Ed Fr. 1993 May;60:335–341.
    1. Marty M, Blotman F, Avouac B, Rozenberg S, Valat JP. Validation of the French version of the Dallas pain questionnaire in chronic low back pain patients. Reu Rheum Engl Ed 1. 1998;8:65.
    1. Sanchez K, Papelard A, Nguyen C, Bendeddouche I, Jousse M, Rannou F, Revel M, Poiraudeau S. McMaster-Toronto Arthritis Patient Preference Disability Questionnaire sensitivity to change in low back pain: influence of shifts in priorities. PLoS One. 2011;6:e20274. doi: 10.1371/journal.pone.0020274.
    1. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, van der Heijde D, Wells G, Dougados M. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007 May;34:1188–1193.
    1. Shapiro SS, Wilk MB. An Analysis of Variance Test for Normality (Complete Samples) Biometrika. Vol. 52, No. 3/4. London, UK: Biometrika Trust; 1965:591-611.
    1. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY, USA: Springer; 2000. pp. 201–230.
    1. Royston P. The Stata Journal. College Station, TX, USA: Stata Press; 2004. Multiple imputation of missing values; pp. 227–241. (Volume 4, Number 3).
    1. Souberbielle JC, Prié D, Courbebaisse M, Friedlander G, Houillier P, Maruani G, Cavalier E, Cormier C. Update on vitamin D and evaluation of vitamin D status. Ann Endocrinol (Paris) 2008 Dec;69:501–510. doi: 10.1016/j.ando.2008.07.010.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner